Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tissue Regenix ( (GB:TRX) ) just unveiled an announcement.
Shareholders of Tissue Regenix have approved all resolutions at a general meeting, enabling the issue of an initial £7.5m tranche of secured convertible loan notes from Harwood Private Equity, funding that management says is essential to restore payments to creditors, stabilise operations and execute a recovery plan aimed at returning the company to profitability. The vote also clears the way for the company’s shares to be delisted from AIM on 7 January 2026, after which Tissue Regenix will re-register as a private limited company and offer shareholders periodic trading through the Asset Match secondary market, marking a significant shift in its capital markets presence while securing short-term financial viability for its regenerative medicine business.
The most recent analyst rating on (GB:TRX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.
Spark’s Take on GB:TRX Stock
According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.
Tissue Regenix faces significant financial and operational challenges, reflected in its negative earnings and reliance on external funding. Technical indicators suggest bearish momentum, and recent corporate events highlight financial instability. While there are strategic efforts to improve, the immediate outlook remains cautious.
To see Spark’s full report on GB:TRX stock, click here.
More about Tissue Regenix
Tissue Regenix Group plc is a UK-based regenerative medical devices company focused on regenerative medicine. Its patented dCELL decellularisation technology produces acellular tissue scaffolds from human and animal soft tissue for use in repairing damaged or diseased body structures, with current products targeting sports medicine, foot and ankle injuries and wound care. Through its CellRight Technologies acquisition, the group also supplies human tissue scaffolds used in spine, trauma, general orthopaedic, dental and ophthalmological procedures.
Average Trading Volume: 1,053,307
Technical Sentiment Signal: Sell
Current Market Cap: £5.16M
For an in-depth examination of TRX stock, go to TipRanks’ Overview page.